Zak Mir interviews John Taylor, CEO of Pathfinder Minerals. Click the play button below to listen to the audio.
Following on from last week’s RNS that there is now 100% of the current owners of the licence involved in the sale negotiations – is it fair to say this is a game changer for the company?
There have been many false dawns in PFP over recent years regarding a resolution and some remain understandably skeptical of a deal actually being concluded – can you explain why this time really is different?
I note that CEO John Taylor bought into the warrant and loan package which was at a premium – what can shareholders take away from this?
Can you elaborate on the sheer magnitude of the prize at hand here given the most recent scoping study valuing the project at over $1bn?
A number of commentators are fearful of future dilution on a deal conclusion – how do you intend to address this?
Finally, how do you see the hoped for resolution end game for shareholders playing out during the next few months?
For more comments on Pathfinder visit http://www.alignresearch.co.uk/cpt-company/pathfinder-minerals/
RISK WARNING & DISCLAIMER
Pathfinder is a research client of Align Research. Align Research and a director of Align Research own shares in Pathfinder and are bound to the company’s dealing policy ensuring open and adequate disclosure. Full details can be found on our website here (“Legals”).
This is a marketing communication and cannot be considered independent research. Nothing in this report should be construed as advice, an offer, or the solicitation of an offer to buy or sell securities by us. As we have no knowledge of your individual situation and circumstances the investment(s) covered may not be suitable for you. You should not make any investment decision without consulting a fully qualified financial advisor.
Your capital is at risk by investing in securities and the income from them may fluctuate. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results. The marketability of some of the companies we cover is limited and you may have difficulty buying or selling in volume. Additionally, given the smaller capitalisation bias of our coverage, the companies we cover should be considered as high risk.
This financial promotion has been approved by Align Research Limited